Form 8-K - Current report:
SEC Accession No. 0001193125-26-130372
Filing Date
2026-03-30
Accepted
2026-03-30 06:58:50
Documents
11
Period of Report
2026-03-30
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nmra-20260330.htm   iXBRL 8-K 46757
2 EX-99.1 nmra-ex99_1.htm EX-99.1 192896
3 GRAPHIC img49001591_0.gif GRAPHIC 5017
  Complete submission text file 0001193125-26-130372.txt   362202

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT nmra-20260330.xsd EX-101.SCH 23893
14 EXTRACTED XBRL INSTANCE DOCUMENT nmra-20260330_htm.xml XML 4535
Mailing Address 260 ARSENAL PLACE, SUITE 1 WATERTOWN MA 02472
Business Address 260 ARSENAL PLACE, SUITE 1 WATERTOWN MA 02472 (857) 760-0900
Neumora Therapeutics, Inc. (Filer) CIK: 0001885522 (see all company filings)

EIN.: 844367680 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41802 | Film No.: 26809923
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)